Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa. The study aims to assess the disease activity and safety of Lutikizumab, an investigational drug, in treating moderate to severe Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition.
The intervention being tested is Lutikizumab, administered via subcutaneous injections. It is designed to alleviate the symptoms of HS by targeting specific inflammatory pathways, with the study comparing its effects against a placebo.
The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is treatment-focused, aiming to provide insights into the efficacy and safety of Lutikizumab.
The study began on June 27, 2024, with primary completion expected by August 5, 2025. The last update was submitted on August 5, 2025, indicating ongoing recruitment and progress.
For investors, this study represents a significant potential for AbbVie, as successful results could enhance its market position in dermatology treatments. The competitive landscape includes other pharmaceutical companies developing treatments for HS, which could influence stock performance and investor sentiment depending on trial outcomes.
The study is ongoing, with further details available on the ClinicalTrials portal.